OMER - Omeros Corp Stock Price, Fair Value and News

3.44USD+0.13 (+3.93%)Delayed

Market Summary

USD3.44+0.13

Delayed

3.93%

OMER Stock Price

View Fullscreen

OMER RSI Chart

OMER Valuation

Market Cap

199.3M

Price/Earnings (Trailing)

-1.64

Price/Sales (Trailing)

13.1

EV/EBITDA

-2.47

Price/Free Cashflow

-1.4

OMER Price/Sales (Trailing)

OMER Profitability

EBT Margin

-1195.99%

Return on Equity

170.05%

Return on Assets

-27.73%

Free Cashflow Yield

-71.29%

OMER Fundamentals

OMER Revenue

Revenue (TTM)

15.2M

Rev. Growth (Yr)

-13.83%

Rev. Growth (Qtr)

-0.41%

OMER Earnings

Earnings (TTM)

-121.3M

Earnings Growth (Yr)

-10.34%

Earnings Growth (Qtr)

-310.06%

Breaking Down OMER Revenue

Last 7 days

-2.0%

Last 30 days

3.0%

Last 90 days

-29.6%

Trailing 12 Months

-40.4%

How does OMER drawdown profile look like?

OMER Financial Health

Current Ratio

4.76

Debt/Equity

-1.85

Debt/Cashflow

-1.08

OMER Investor Care

Buy Backs (1Y)

7.77%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	15.2M	0	0	0
2023	7.4M	0	11.3M	13.8M
2022	2.5M	0	3.3M	4.1M
2021	71.3M	86.6M	44.2M	1.7M
2020	113.6M	100.3M	96.6M	73.8M
2019	50.1M	75.2M	100.4M	111.8M
2018	56.1M	47.3M	38.6M	29.9M
2017	46.5M	53.6M	64.0M	64.8M
2016	20.4M	27.2M	35.2M	41.4M
2015	827.0K	4.0M	7.0M	13.5M
2014	605.0K	510.0K	528.0K	539.0K
2013	5.6M	4.2M	3.0M	1.6M
2012	4.8M	5.2M	5.6M	6.0M
2011	3.0M	3.6M	4.4M	4.5M
2010	0	1.7M	1.9M	2.1M
2009	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Omeros Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 17, 2023	demopulos gregory a md	bought	25,200	1.68	15,000	chairman, ceo & president
Nov 15, 2023	demopulos peter a md	bought	15,300	1.53	10,000	-
Nov 14, 2023	demopulos gregory a md	acquired	36,000	1.44	25,000	chairman, ceo & president
Nov 13, 2023	demopulos gregory a md	acquired	48,375	1.29	37,500	chairman, ceo & president
Sep 12, 2023	bumol thomas f.	acquired	33,100	3.31	10,000	-
May 22, 2023	hanish arnold c	sold	-32,300	6.46	-5,000	-
May 22, 2023	hanish arnold c	acquired	26,500	5.3	5,000	-
May 22, 2023	cable thomas j.	sold	-32,650	6.53	-5,000	-
May 22, 2023	cable thomas j.	acquired	26,500	5.3	5,000	-
Sep 08, 2021	hanish arnold c	acquired	94,400	9.44	10,000	-

Which funds bought or sold OMER recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	B. Riley Wealth Advisors, Inc.	added	6.95	-2,113	44,910	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-80.28	-170,850	44,888	-%
May 16, 2024	COMERICA BANK	added	20.00	21,750	103,500	-%
May 16, 2024	Ancora Advisors LLC	reduced	-27.29	-124,143	408,942	0.01%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.91	-11,648	21,117	-%
May 15, 2024	Squarepoint Ops LLC	sold off	-100	-122,664	-	-%
May 15, 2024	TOWNSQUARE CAPITAL LLC	new	-	67,248	67,248	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	6.83	14,000	122,000	-%
May 15, 2024	Saltoro Capital, LP	sold off	-100	-600,000	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-35.38	-177,135	379,456	-%

Are Funds Buying or Selling OMER?

Are funds buying OMER calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OMER

No. of Funds

Unveiling Omeros Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 27, 2024	ingalls & snyder llc	7.0%	4,431,188	SC 13G/A
Feb 14, 2024	demopulos gregory a md	8.80%	5,704,061	SC 13G/A
Feb 13, 2024	vanguard group inc	5.04%	3,168,936	SC 13G
Jan 29, 2024	blackrock inc.	6.8%	4,279,836	SC 13G
Feb 17, 2023	ingalls & snyder llc	6.6%	4,131,793	SC 13G/A
Feb 14, 2023	demopulos gregory a md	8.37%	5,551,980	SC 13G/A
Feb 09, 2023	vanguard group inc	4.50%	2,820,445	SC 13G/A
Jul 08, 2022	blackrock inc.	2.0%	1,225,787	SC 13G
Feb 14, 2022	demopulos gregory a md	8.07%	5,314,624	SC 13G/A
Feb 14, 2022	cormorant asset management, lp	0%	0	SC 13G/A

Recent SEC filings of Omeros Corp

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	ARS	ARS
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 01, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Mar 27, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Omeros Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Omeros Corp News

Latest updates

Omeros Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-0.4%	3,415,000	3,429,000	4,413,000	3,963,000	1,993,000	906,000	493,000	9,936,333	19,379,667	28,823,000	21,061,000	10,632,000	26,114,000	13,530,000	23,537,000	33,417,000	29,856,000	26,753,000	21,779,000	22,017,000	4,608,000
Costs and Expenses	-1.8%	39,034,000	39,765,000	48,153,000	35,713,000	40,138,500	50,766,000	35,046,000	42,889,000	39,828,000	45,610,000	45,290,000	44,448,000	51,542,000	41,210,000	47,214,000	57,121,000	40,957,000	36,091,000	41,018,000	40,491,000	40,050,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	41,018,000	40,491,000	40,050,000
S&GA Expenses	12.8%	12,264,000	10,875,000	16,422,000	11,103,000	13,589,000	12,198,000	10,959,000	12,562,000	14,010,000	15,484,000	12,786,000	-5,486,000	19,825,000	16,931,000	18,036,000	-8,779,000	16,933,000	16,928,000	14,632,000	14,888,000	13,152,000
R&D Expenses	-7.3%	26,770,000	28,890,000	31,731,000	24,610,000	26,549,500	38,568,000	24,087,000	30,327,000	25,818,000	30,126,000	32,504,000	23,253,000	31,316,000	24,132,000	28,911,000	37,215,500	23,746,000	19,108,000	26,255,000	25,446,000	26,862,000
EBITDA Margin	9.5%	-9.85	-10.89	-13.26	-21.14	-38.99	-73.32	-95.83	-138	-5.53	-2.73	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	16.5%	8,231,000	7,063,000	7,916,000	7,933,000	7,902,500	4,932,000	4,941,000	4,951,000	4,911,000	4,910,000	4,897,000	7,988,000	6,882,000	5,978,000	5,903,000	5,811,500	5,715,000	5,530,000	5,600,000	5,148,500	4,602,000
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-15,402,000	-7,854,000	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-105,160,000	-22,703,000	-	-	-87,747,000	-46,317,000	-	-	-111,881,000	-16,463,000	-	-	-	-
EBT Margin	9.3%	-11.96	-13.19	-16.14	-24.75	-44.81	-79.66	-104	-150	-6.08	-3.03	-	-	-	-	-	-	-	-	-	-	-
Net Income	-310.1%	-37,184,000	-9,068,000	-37,750,000	-33,701,000	128,733,000	-17,456,000	-33,011,000	280,621,000	-22,703,000	-28,593,000	-35,090,000	-37,273,000	-38,463,000	-33,294,000	-29,031,000	-29,225,000	-16,463,000	-14,453,000	-24,345,000	-23,534,000	-39,472,000
Net Income Margin	6.7%	-7.97	-8.54	1.77	6.35	11.67	60.62	78.09	111	-2.80	-1.61	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-19.5%	-41,838,000	-35,018,000	-32,631,000	174,539,000	-25,395,000	-26,436,000	-15,267,000	-18,289,000	-23,764,000	-27,680,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	15.7%	437	378	493	527	560	591	458	346	369	419	123	145	161	181	227	71.00	118	137	91.00	90.00	101
Current Assets	28.9%	281	218	351	389	417	443	289	193	210	248	91.00	112	132	151	196	39.00	86.00	104	64.00	66.00	77.00
Cash Equivalents	-74.2%	2.00	7.00	31.00	7.00	4.00	11.00	146	14.00	9.00	101	7.00	13.00	9.00	11.00	21.00	2.00	7.00	3.00	9.00	4.00	4.00
Inventory	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00	1.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00
Net PPE	-7.5%	2.00	2.00	2.00	-	-	1.00	-	-	-	-	-	-	-	-	3.00	3.00	3.00	4.00	4.00	4.00	4.00
Current Liabilities	10.8%	59.00	53.00	147	144	139	136	40.00	39.00	35.00	52.00	43.00	48.00	43.00	37.00	48.00	38.00	58.00	55.00	47.00	41.00	45.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00
Shareholder's Equity	-185.5%	-71.33	-24.98	-	21.00	55.00	86.00	-	-	-	24.00	-	-	-	-120	-	-	-	-	-	-	-
Retained Earnings	-4.9%	-790	-753	-744	-706	-669	-635	-764	-746	-716	-683	-963	-941	-912	-872	-835	-796	-763	-734	-705	-688	-674
Additional Paid-In Capital	-1.3%	719	728	730	727	724	721	718	714	711	706	700	694	690	751	747	635	631	625	565	558	553
Shares Outstanding	-5.2%	58.00	61.00	63.00	63.00	63.00	63.00	63.00	63.00	63.00	62.00	62.00	62.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	328	-	-	-	166	-	-	-	887	-	-	-	762	-	-	-	729	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-19.7%	-41,780	-34,900	-32,598	-32,341	174,539	-25,382	-26,439	-19,469	-15,193	-18,215	-23,661	-27,592	-40,254	-18,407	-34,941	-37,597	-9,141	-23,014	-7,522	-16,589	-12,948
Share Based Compensation	-1.2%	2,658	2,691	3,235	2,771	2,953	3,264	3,844	3,072	3,892	5,548	5,694	3,117	3,271	3,803	3,824	3,822	3,476	3,317	3,496	3,598	3,374
Cashflow From Investing	-153.3%	-61,925	116,243	57,167	35,375	-181,331	-108,491	32,999	24,741	-76,813	112,418	17,896	30,411	32,985	7,996	-118,397	32,594	10,776	-39,239	9,339	15,212	11,287
Cashflow From Financing	193.8%	98,431	-104,953	-483	-260	-388	-651	124,837	-99.00	161	-810	478	855	5,796	-163	172,449	-151	2,399	56,476	3,058	1,309	-146
Buy Backs	-	11,851	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OMER Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Costs and expenses:
Research and development	$ 26,770	$ 24,610
Selling, general and administrative	12,264	11,103
Total costs and expenses	39,034	35,713
Loss from operations	(39,034)	(35,713)
Interest expense	(8,231)	(7,933)
Interest and other income	3,415	3,963
Net loss from continuing operations	(43,850)	(39,683)
Net income from discontinued operations, net of tax	6,666	5,982
Net loss	$ (37,184)	$ (33,701)
Basic and diluted net income (loss) per share:
Net loss from continuing operations (in dollars per share)	$ (0.75)	$ (0.63)
Net income from discontinued operations (in dollars per share)	0.12	0.09
Net loss (in dollars per share)	$ (0.63)	$ (0.54)
Weighted-average shares used to compute basic and diluted net income (loss) per share (in shares)	58,800,716	62,828,765

OMER Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,831	$ 7,105
Short-term investments	228,503	164,743
OMIDRIA contract royalty asset, short-term	29,519	29,373
Receivables	7,642	8,096
Prepaid expense and other assets	13,463	8,581
Total current assets	280,958	217,898
OMIDRIA contract royalty asset	135,909	138,736
Right of use assets	17,767	18,631
Property and equipment, net	1,804	1,950
Restricted investments	1,054	1,054
Total assets	437,492	378,269
Current liabilities:
Accounts payable	6,182	7,712
Accrued expenses	28,402	31,868
Current portion of OMIDRIA royalty obligation	19,130	8,576
Current portion of lease liabilities	5,342	5,160
Total current liabilities	59,056	53,316
Convertible senior notes, net	213,463	213,155
OMIDRIA royalty obligation, non-current	217,459	116,550
Lease liabilities, non-current	16,754	18,143
Other accrued liabilities, non-current	2,088	2,088
Commitments and contingencies (Note 10)
Shareholders’ equity (deficit):
Preferred stock, par value $0.01 per share, 20,000,000 shares authorized; none issued and outstanding at March 31, 2024 and December 31, 2023.	0	0
Common stock, par value $0.01 per share, 150,000,000 shares authorized at March 31, 2024 and December 31, 2023; 57,942,695 and 61,128,597 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively.	579	611
Additional paid-in capital	718,807	727,936
Accumulated deficit	(790,714)	(753,530)
Total shareholders’ deficit	(71,328)	(24,983)
Total liabilities and shareholders’ equity (deficit)	$ 437,492	$ 378,269

About Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

CEO	Dr. Gregory A. Demopulos M.D.
WEBSITE	omeros.com
INDUSTRY	Biotechnology
EMPLOYEES	196

Omeros Corp Frequently Asked Questions

What is the ticker symbol for Omeros Corp? What does OMER stand for in stocks?

OMER is the stock ticker symbol of Omeros Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Omeros Corp (OMER)?

As of Fri May 17 2024, market cap of Omeros Corp is 199.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OMER stock?

You can check OMER's fair value in chart for subscribers.

What is the fair value of OMER stock?

You can check OMER's fair value in chart for subscribers. The fair value of Omeros Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Omeros Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OMER so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Omeros Corp a good stock to buy?

The fair value guage provides a quick view whether OMER is over valued or under valued. Whether Omeros Corp is cheap or expensive depends on the assumptions which impact Omeros Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OMER.

What is Omeros Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, OMER's PE ratio (Price to Earnings) is -1.64 and Price to Sales (PS) ratio is 13.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OMER PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Omeros Corp's stock?

In the past 10 years, Omeros Corp has provided -0.102 (multiply by 100 for percentage) rate of return.